select a format

Single User License
USD 2000 INR 130040
Site License
USD 4000 INR 260080
Corporate User License
USD 6000 INR 390120

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Ebola Viral Infections-Pipeline Review, H2 2015

Ebola Viral Infections-Pipeline Review, H2 2015


  • Products Id :- GMDHC7222IDB
  • |
  • Pages: 235
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Ebola Viral Infections-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Ebola Viral Infections-Pipeline Review, H2 2015', provides an overview of the Ebola Viral Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Ebola Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Ebola Viral Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Ebola Viral Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Ebola Viral Infections Overview 9

Therapeutics Development 10

Pipeline Products for Ebola Viral Infections-Overview 10

Pipeline Products for Ebola Viral Infections-Comparative Analysis 11

Ebola Viral Infections-Therapeutics under Development by Companies 12

Ebola Viral Infections-Therapeutics under Investigation by Universities/Institutes 17

Ebola Viral Infections-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Unknown Stage Products 22

Ebola Viral Infections-Products under Development by Companies 23

Ebola Viral Infections-Products under Investigation by Universities/Institutes 28

Ebola Viral Infections-Companies Involved in Therapeutics Development 29

Abivax S.A. 29

AmVac AG 30

AnGes MG, Inc. 31

Arno Therapeutics, Inc. 32

Canopus BioPharma Incorporated 33

Crucell N.V. 34

Emergent BioSolutions Inc. 35

Enyo Pharma S.A.S. 36

Epirus Biopharmaceuticals, Inc. 37

Etubics Corporation 38

FIT Biotech Oy 39

Gilead Sciences, Inc. 40

GlaxoSmithKline Plc 41

Globavir Biosciences, Inc. 42

Hemispherx Biopharma, Inc. 43

Humabs BioMed SA 44

Immune Response BioPharma, Inc. 45

Immunovaccine, Inc. 46

Inovio Pharmaceuticals, Inc. 47

Kineta, Inc. 48

Kymab Limited 49

Medicago Inc. 50

Merck & Co., Inc. 51

Microbiotix, Inc. 52

Micropharm Limited 53

Navigen Pharmaceuticals, Inc. 54

Novavax, Inc. 55

Peregrine Pharmaceuticals, Inc. 56

Phelix Therapeutics, LLC 57

RedHill Biopharma Ltd. 58

Regeneron Pharmaceuticals, Inc. 59

SignPath Pharma Inc 60

Sihuan Pharmaceutical Holdings Group Ltd. 61

SKAU Vaccines ApS 62

Tamir Biotechnology, Inc. 63

Toyama Chemical Co., Ltd. 64

United Therapeutics Corporation 65

Vaxeal Holding SA 66

XBiotech USA, Inc. 67

Ebola Viral Infections-Therapeutics Assessment 68

Assessment by Monotherapy Products 68

Assessment by Combination Products 69

Assessment by Target 70

Assessment by Mechanism of Action 72

Assessment by Route of Administration 74

Assessment by Molecule Type 76

Drug Profiles 78

ABX-544-Drug Profile 78

Ad5-EBOV vaccine-Drug Profile 79

AMV-701-Drug Profile 80

ANSX-109-Drug Profile 81

ANSX-142-Drug Profile 82

Antibody for Ebola Viral Infection-Drug Profile 83

AR-12-Drug Profile 84

bavituximab-Drug Profile 86

CB-007-Drug Profile 91

CB-008-Drug Profile 92

DEF-201-Drug Profile 93

DLANA-14-Drug Profile 95

DPX-Ebola-Drug Profile 96

Drug for Ebola Virus Infection-Drug Profile 97

Drugs to Inhibit Cathepsin B for Ebola Viral Infections-Drug Profile 98

Drugs to Inhibit Cathepsin L for Infectious Diseases-Drug Profile 99

ebola + rabies vaccine-Drug Profile 100

ebola [strain sudan, zaire] + marburg vaccine-Drug Profile 101

ebola [strain zaire] (monovalent) vaccine-Drug Profile 103

ebola [strain zaire] vaccine-Drug Profile 104

ebola [zaire] vaccine-Drug Profile 107

ebola [zaire] vaccine-Drug Profile 108

ebola vaccine-Drug Profile 109

ebola vaccine-Drug Profile 110

ebola vaccine-Drug Profile 112

ebola vaccine-Drug Profile 113

ebola vaccine-Drug Profile 114

ebola vaccine-Drug Profile 115

ebola vaccine-Drug Profile 117

ebola vaccine-Drug Profile 118

ebola vaccine-Drug Profile 119

ebola vaccine 1-Drug Profile 120

ebola vaccine 2-Drug Profile 121

ebola virus like particle vaccine-Drug Profile 122

ebola virus like particle vaccine-Drug Profile 123

Ebola virus vaccine-Drug Profile 124

EBOTAb-Drug Profile 125

ET-007-Drug Profile 126

favipiravir-Drug Profile 127

FBH-004-Drug Profile 129

FDX-000-Drug Profile 130

GBV-006-Drug Profile 131

Gene Therapy for Ebola Virus Infections-Drug Profile 132

GreEMTri-Drug Profile 133

GS-5734-Drug Profile 134

imatinib mesylate-Drug Profile 135

INO-4212-Drug Profile 136

interferon alfa-n3-Drug Profile 137

IRE-101-Drug Profile 138

JK-05-Drug Profile 139

KV-7005-Drug Profile 140

Lipocurc-Drug Profile 141

MIL-77-Drug Profile 143

MMCatLMC-Drug Profile 144

Monoclonal Antibodies for Ebola Viral Infections-Drug Profile 145

Monoclonal Antibodies for Ebola Virus Infection-Drug Profile 146

Monoclonal Antibodies for Viral Infections-Drug Profile 147

MonoClonal Antibody for Ebola and Marburg Infections-Drug Profile 149

Monoclonal Antibody for Ebola Viral Infections-Drug Profile 150

Monoclonal Antibody for Ebola Virus Infections-Drug Profile 151

NCK-8-Drug Profile 152

NoBola-Drug Profile 153

OS-2966-Drug Profile 154

rintatolimod-Drug Profile 155

Small Molecule to Agonize IRF-3 for Viral Infections-Drug Profile 157

Small Molecule to Inhibit Cathepsin L for SARS and Ebola Viral Infections-Drug Profile 158

Small Molecules for Ebola Viral Infections-Drug Profile 159

Small Molecules for Ebola Virus Infection-Drug Profile 160

Small Molecules for Ebola Virus Infections-Drug Profile 161

Small Molecules to Inhibit Cathepsin L for Ebola Virus Infection-Drug Profile 162

Small Molecules to Inhibit Niemann Pick C1 for Ebola Viral Infections-Drug Profile 163

Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus-Drug Profile 164

Small Molecules to Inhibit Nucleoprotein for Ebola Virus Infections-Drug Profile 165

Small Molecules to Target Estrogen Receptor for Ebola Virus Infection-Drug Profile 166

Synthetic Peptides for Ebola Virus-Drug Profile 167

thiocarbazate-Drug Profile 168

TMR-004-Drug Profile 169

UV-4B-Drug Profile 170

V-920-Drug Profile 171

ZMAb-Drug Profile 174

ZMapp-Drug Profile 176

Ebola Viral Infections-Recent Pipeline Updates 178

Ebola Viral Infections-Dormant Projects 217

Ebola Viral Infections-Discontinued Products 219

Ebola Viral Infections-Product Development Milestones 220

Featured News & Press Releases 220

Appendix 228

Methodology 228

Coverage 228

Secondary Research 228

Primary Research 228

Expert Panel Validation 228

Contact Us 228

Disclaimer 229

List of Tables

Number of Products under Development for Ebola Viral Infections, H2 2015 16

Number of Products under Development for Ebola Viral Infections-Comparative Analysis, H2 2015 17

Number of Products under Development by Companies, H2 2015 19

Number of Products under Development by Companies, H2 2015 (Contd..1) 20

Number of Products under Development by Companies, H2 2015 (Contd..2) 21

Number of Products under Development by Companies, H2 2015 (Contd..3) 22

Number of Products under Investigation by Universities/Institutes, H2 2015 24

Comparative Analysis by Late Stage Development, H2 2015 25

Comparative Analysis by Clinical Stage Development, H2 2015 26

Comparative Analysis by Early Stage Development, H2 2015 27

Comparative Analysis by Unknown Stage Development, H2 2015 28

Products under Development by Companies, H2 2015 29

Products under Development by Companies, H2 2015 (Contd..1) 30

Products under Development by Companies, H2 2015 (Contd..2) 31

Products under Development by Companies, H2 2015 (Contd..3) 32

Products under Development by Companies, H2 2015 (Contd..4) 33

Products under Investigation by Universities/Institutes, H2 2015 34

Ebola Viral Infections-Pipeline by Abivax S.A., H2 2015 35

Ebola Viral Infections-Pipeline by AmVac AG, H2 2015 36

Ebola Viral Infections-Pipeline by AnGes MG, Inc., H2 2015 37

Ebola Viral Infections-Pipeline by Arno Therapeutics, Inc., H2 2015 38

Ebola Viral Infections-Pipeline by Canopus BioPharma Incorporated, H2 2015 39

Ebola Viral Infections-Pipeline by Crucell N.V., H2 2015 40

Ebola Viral Infections-Pipeline by Emergent BioSolutions Inc., H2 2015 41

Ebola Viral Infections-Pipeline by Enyo Pharma S.A.S., H2 2015 42

Ebola Viral Infections-Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 43

Ebola Viral Infections-Pipeline by Etubics Corporation, H2 2015 44

Ebola Viral Infections-Pipeline by FIT Biotech Oy, H2 2015 45

Ebola Viral Infections-Pipeline by Gilead Sciences, Inc., H2 2015 46

Ebola Viral Infections-Pipeline by GlaxoSmithKline Plc, H2 2015 47

Ebola Viral Infections-Pipeline by Globavir Biosciences, Inc., H2 2015 48

Ebola Viral Infections-Pipeline by Hemispherx Biopharma, Inc., H2 2015 49

Ebola Viral Infections-Pipeline by Humabs BioMed SA, H2 2015 50

Ebola Viral Infections-Pipeline by Immune Response BioPharma, Inc., H2 2015 51

Ebola Viral Infections-Pipeline by Immunovaccine, Inc., H2 2015 52

Ebola Viral Infections-Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 53

Ebola Viral Infections-Pipeline by Kineta, Inc., H2 2015 54

Ebola Viral Infections-Pipeline by Kymab Limited, H2 2015 55

Ebola Viral Infections-Pipeline by Medicago Inc., H2 2015 56

Ebola Viral Infections-Pipeline by Merck & Co., Inc., H2 2015 57

Ebola Viral Infections-Pipeline by Microbiotix, Inc., H2 2015 58

Ebola Viral Infections-Pipeline by Micropharm Limited, H2 2015 59

Ebola Viral Infections-Pipeline by Navigen Pharmaceuticals, Inc., H2 2015 60

Ebola Viral Infections-Pipeline by Novavax, Inc., H2 2015 61

Ebola Viral Infections-Pipeline by Peregrine Pharmaceuticals, Inc., H2 2015 62

Ebola Viral Infections-Pipeline by Phelix Therapeutics, LLC, H2 2015 63

Ebola Viral Infections-Pipeline by RedHill Biopharma Ltd., H2 2015 64

Ebola Viral Infections-Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015 65

Ebola Viral Infections-Pipeline by SignPath Pharma Inc, H2 2015 66

Ebola Viral Infections-Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2015 67

Ebola Viral Infections-Pipeline by SKAU Vaccines ApS, H2 2015 68

Ebola Viral Infections-Pipeline by Tamir Biotechnology, Inc., H2 2015 69

Ebola Viral Infections-Pipeline by Toyama Chemical Co., Ltd., H2 2015 70

Ebola Viral Infections-Pipeline by United Therapeutics Corporation, H2 2015 71

Ebola Viral Infections-Pipeline by Vaxeal Holding SA, H2 2015 72

Ebola Viral Infections-Pipeline by XBiotech USA, Inc., H2 2015 73

Assessment by Monotherapy Products, H2 2015 74

Assessment by Combination Products, H2 2015 75

Number of Products by Stage and Target, H2 2015 77

Number of Products by Stage and Mechanism of Action, H2 2015 79

Number of Products by Stage and Route of Administration, H2 2015 81

Number of Products by Stage and Molecule Type, H2 2015 83

Ebola Viral Infections Therapeutics-Recent Pipeline Updates, H2 2015 184

Ebola Viral Infections-Dormant Projects, H2 2015 223

Ebola Viral Infections-Dormant Projects (Contd..1), H2 2015 224

Ebola Viral Infections-Discontinued Products, H2 2015 225

List of Figures

Number of Products under Development for Ebola Viral Infections, H2 2015 16

Number of Products under Development for Ebola Viral Infections-Comparative Analysis, H2 2015 17

Number of Products under Development by Companies, H2 2015 18

Number of Products under Investigation by Universities/Institutes, H2 2015 23

Comparative Analysis by Clinical Stage Development, H2 2015 26

Comparative Analysis by Early Stage Products, H2 2015 27

Assessment by Monotherapy Products, H2 2015 74

Assessment by Combination Products, H2 2015 75

Number of Products by Top 10 Targets, H2 2015 76

Number of Products by Stage and Top 10 Targets, H2 2015 76

Number of Products by Top 10 Mechanism of Actions, H2 2015 78

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 78

Number of Products by Routes of Administration, H2 2015 80

Number of Products by Stage and Routes of Administration, H2 2015 80

Number of Products by Top 10 Molecule Types, H2 2015 82

Number of Products by Stage and Top 10 Molecule Types, H2 2015 82

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Abivax S.A.

AmVac AG

AnGes MG, Inc.

Arno Therapeutics, Inc.

Canopus BioPharma Incorporated

Crucell N.V.

Emergent BioSolutions Inc.

Enyo Pharma S.A.S.

Epirus Biopharmaceuticals, Inc.

Etubics Corporation

FIT Biotech Oy

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Globavir Biosciences, Inc.

Hemispherx Biopharma, Inc.

Humabs BioMed SA

Immune Response BioPharma, Inc.

Immunovaccine, Inc.

Inovio Pharmaceuticals, Inc.

Kineta, Inc.

Kymab Limited

Medicago Inc.

Merck & Co., Inc.

Microbiotix, Inc.

Micropharm Limited

Navigen Pharmaceuticals, Inc.

Novavax, Inc.

Peregrine Pharmaceuticals, Inc.

Phelix Therapeutics, LLC

RedHill Biopharma Ltd.

Regeneron Pharmaceuticals, Inc.

SignPath Pharma Inc

Sihuan Pharmaceutical Holdings Group Ltd.

SKAU Vaccines ApS

Tamir Biotechnology, Inc.

Toyama Chemical Co., Ltd.

United Therapeutics Corporation

Vaxeal Holding SA

XBiotech USA, Inc.

Ebola Viral Infections Therapeutic Products under Development, Key Players in Ebola Viral Infections Therapeutics, Ebola Viral Infections Pipeline Overview, Ebola Viral Infections Pipeline, Ebola Viral Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com